<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p69" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_69{left:130px;bottom:1196px;letter-spacing:-0.15px;}
#t2_69{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_69{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_69{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_69{left:238px;bottom:1061px;letter-spacing:-0.01px;}
#t6_69{left:238px;bottom:1026px;letter-spacing:-0.01px;}
#t7_69{left:238px;bottom:1007px;letter-spacing:-0.01px;}
#t8_69{left:238px;bottom:988px;letter-spacing:-0.01px;}
#t9_69{left:238px;bottom:968px;letter-spacing:-0.01px;}
#ta_69{left:238px;bottom:949px;letter-spacing:-0.01px;}
#tb_69{left:238px;bottom:875px;letter-spacing:-0.01px;}
#tc_69{left:238px;bottom:840px;letter-spacing:-0.01px;}
#td_69{left:238px;bottom:821px;letter-spacing:-0.01px;}
#te_69{left:238px;bottom:801px;letter-spacing:-0.01px;}
#tf_69{left:238px;bottom:782px;letter-spacing:-0.01px;}
#tg_69{left:238px;bottom:763px;letter-spacing:-0.01px;}
#th_69{left:238px;bottom:743px;letter-spacing:-0.01px;}
#ti_69{left:238px;bottom:670px;letter-spacing:-0.01px;}
#tj_69{left:238px;bottom:635px;letter-spacing:-0.01px;}
#tk_69{left:238px;bottom:615px;letter-spacing:-0.01px;}
#tl_69{left:238px;bottom:596px;letter-spacing:-0.01px;}
#tm_69{left:238px;bottom:577px;letter-spacing:-0.01px;}
#tn_69{left:238px;bottom:557px;letter-spacing:-0.01px;}
#to_69{left:238px;bottom:503px;letter-spacing:-0.01px;}
#tp_69{left:238px;bottom:484px;letter-spacing:-0.01px;}
#tq_69{left:238px;bottom:464px;letter-spacing:-0.01px;}
#tr_69{left:238px;bottom:445px;letter-spacing:-0.01px;}
#ts_69{left:238px;bottom:425px;letter-spacing:-0.01px;}
#tt_69{left:238px;bottom:406px;letter-spacing:-0.01px;}
#tu_69{left:238px;bottom:386px;letter-spacing:-0.01px;}
#tv_69{left:238px;bottom:367px;letter-spacing:-0.01px;}
#tw_69{left:238px;bottom:348px;letter-spacing:-0.01px;}
#tx_69{left:238px;bottom:328px;letter-spacing:-0.01px;}
#ty_69{left:238px;bottom:309px;letter-spacing:-0.01px;}
#tz_69{left:238px;bottom:289px;letter-spacing:-0.01px;}
#t10_69{left:238px;bottom:196px;letter-spacing:-0.01px;}
#t11_69{left:238px;bottom:177px;letter-spacing:-0.01px;}
#t12_69{left:238px;bottom:157px;letter-spacing:-0.01px;}
#t13_69{left:238px;bottom:138px;letter-spacing:-0.01px;}
#t14_69{left:238px;bottom:118px;letter-spacing:-0.01px;}
#t15_69{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_69{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_69{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_69{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts69" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg69Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg69" style="-webkit-user-select: none;"><object width="908" height="1286" data="69/69.svg" type="image/svg+xml" id="pdf69" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_69" class="t s0_69">7.3. Fundamental considerations of multimodal therapy approaches </span><span id="t2_69" class="t s1_69">69 </span>
<span id="t3_69" class="t s2_69">Chemotherapy) or induction chemotherapy followed by radio- or radiochemotherapy </span>
<span id="t4_69" class="t s2_69">represents an alternative to primary surgical intervention </span>
<span id="t5_69" class="t s2_69">Background 7.28. </span>
<span id="t6_69" class="t s2_69">The Veterans Affairs Laryngeal Cancer Study Group randomized 332 patients with </span>
<span id="t7_69" class="t s2_69">laryngectomy-only laryngeal cancer to either laryngectomy followed by postoperative </span>
<span id="t8_69" class="t s2_69">radiotherapy or induction chemotherapy with 2 cycles of cisplatin and 5 fluorouracil. Patients </span>
<span id="t9_69" class="t s2_69">who responded to induction therapy received an additional cycle of chemotherapy followed by </span>
<span id="ta_69" class="t s2_69">radiotherapy alone with 66-76 Gy in conventional fractionation [189]. </span>
<span id="tb_69" class="t s2_69">Background 7.29. </span>
<span id="tc_69" class="t s2_69">With this concept, the larynx could be preserved in 64% of patients. No difference in overall </span>
<span id="td_69" class="t s2_69">survival was observed. The EORTC tested the same concept in a randomized trial in </span>
<span id="te_69" class="t s2_69">hypopharyngeal carcinoma for which surgical laryngectomy was indicated [223, 224]. Larynx </span>
<span id="tf_69" class="t s2_69">preservation after 5 years was only achieved in 35% of patients. Survival was equally poor in </span>
<span id="tg_69" class="t s2_69">both arms at 33% after 5 years. In both studies, no significant differences were observed in the </span>
<span id="th_69" class="t s2_69">acute and late toxicity of both treatment strategies [224]. </span>
<span id="ti_69" class="t s2_69">Background 7.30 and 7.31. </span>
<span id="tj_69" class="t s2_69">In a study of the quality of life of long-term survivors of the Veterans Affairs Study [222], </span>
<span id="tk_69" class="t s2_69">significant advantages were shown for the arm with induction chemotherapy followed by </span>
<span id="tl_69" class="t s2_69">radiotherapy compared with laryngectomy followed by radiotherapy in terms of mental </span>
<span id="tm_69" class="t s2_69">health (SF-36 mental health domain), head and neck-specific pain (HNQOL-pain score), head </span>
<span id="tn_69" class="t s2_69">and neck-specific emotionality (HNQOL-emotion) and the frequency of depression. </span>
<span id="to_69" class="t s2_69">In a subsequent study, the RTOG compared, in a 3-arm randomized trial [187, 188], </span>
<span id="tp_69" class="t s2_69">radiotherapy alone (70 Gy), simultaneous radiochemotherapy (70 Gy + 3x 100 mg/m² cisplatin) </span>
<span id="tq_69" class="t s2_69">and induction chemotherapy followed by radiotherapy (if there was no response to </span>
<span id="tr_69" class="t s2_69">chemotherapy, laryngectomy +/- radiotherapy) in laryngeal carcinomas that could only be </span>
<span id="ts_69" class="t s2_69">treated surgically by laryngectomy. Larynx preservation was significantly better at 81% after 10 </span>
<span id="tt_69" class="t s2_69">years in the arm with simultaneous radiochemotherapy than after radiotherapy alone (62%) or </span>
<span id="tu_69" class="t s2_69">induction chemotherapy followed by radiotherapy (66%). No significant difference in survival </span>
<span id="tv_69" class="t s2_69">was observed. Significant differences in acute and late toxicity were not initially reported, apart </span>
<span id="tw_69" class="t s2_69">from increased hematotoxicity in the induction chemotherapy arm. However, after </span>
<span id="tx_69" class="t s2_69">simultaneous radiochemotherapy, significantly more deaths not caused by laryngeal </span>
<span id="ty_69" class="t s2_69">carcinoma were observed in the long-term follow-up [188]. There is only speculation about the </span>
<span id="tz_69" class="t s2_69">reason for this observation, but no reliable data. </span>
<span id="t10_69" class="t s2_69">When making a decision, the focus should not only be on organ preservation but also on </span>
<span id="t11_69" class="t s2_69">function, since, for example, in the case of locally advanced laryngeal carcinoma with </span>
<span id="t12_69" class="t s2_69">destruction of large parts of the organ, the functional result after radiochemotherapy may be </span>
<span id="t13_69" class="t s2_69">unsatisfactory due to swallowing disorders caused by a late esophageal inlet stricture or </span>
<span id="t14_69" class="t s2_69">chronic aspiration. </span>
<span id="t15_69" class="t s0_69">© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
